Pharmacokinetic-pharmacodynamic modelling of intravenous and oral topiramate and its effect on phonemic fluency in adult healthy volunteers

被引:11
作者
Ahmed, Ghada F. [1 ]
Marino, Susan E. [1 ,2 ]
Brundage, Richard C. [1 ]
Pakhomov, Serguei V. S. [2 ,3 ]
Leppik, Ilo E. [1 ,2 ]
Cloyd, James C. [1 ,4 ]
Clark, Annie [5 ]
Birnbaum, Angela K. [1 ,2 ]
机构
[1] Univ Minnesota, Coll Pharm, Dept Expt & Clin Pharmacol, Minneapolis, MN 55455 USA
[2] Univ Minnesota, Coll Pharm, Ctr Clin & Cognit Neuropharmacol, Minneapolis, MN 55455 USA
[3] Univ Minnesota, Coll Pharm, Pharmaceut Care & Hlth Syst, Minneapolis, MN 55455 USA
[4] Univ Minnesota, Coll Pharm, Ctr Orphan Drug Res, Dept Expt & Clin Pharmacol, Minneapolis, MN 55455 USA
[5] Upsher Smith Labs, Minneapolis, MN USA
基金
美国国家卫生研究院;
关键词
modelling; pharmacodynamics; pharmacokinetics; topiramate; verbal fluency; EPILEPSY; CARBAMAZEPINE; MONOTHERAPY; VALPROATE; THERAPY; MULTICENTER; CHILDREN; PLASMA;
D O I
10.1111/bcp.12556
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
AimsThe aim was to develop a quantitative approach that characterizes the magnitude of and variability in phonemic generative fluency scores as measured by the Controlled Oral Word Association (COWA) test in healthy volunteers after administration of an oral and a novel intravenous (IV) formulation of topiramate (TPM). MethodsNonlinear mixed-effects modelling was used to describe the plasma TPM concentrations resulting from oral or IV administration. A pharmacokinetic-pharmacodynamic (PK-PD) model was developed sequentially to characterize the effect of TPM concentrations on COWA with different distributional assumptions. ResultsTopiramate was rapidly absorbed, with a median time to maximal concentration of 1h and an oral bioavailability of approximate to 100%. Baseline COWA score increased by an average of 12% after the third administration on drug-free sessions. An exponential model described the decline of COWA scores, which decreased by 14.5% for each 1mgl(-1) increase in TPM concentration. The COWA scores were described equally well by both continuous normal and Poisson distributions. ConclusionsThis analysis quantified the effect of TPM exposure on generative verbal fluency as measured by COWA. Repetitive administration of COWA resulted in a better performance, possibly due to a learning effect. The model predicts a 27% reduction in the COWA score at the average observed maximal plasma concentration after a 100mg dose of TPM. The single-dose administration of relatively low TPM doses and narrow range of resultant concentrations in our study were limitations to investigating the PK-PD relationship at higher TPM exposures. Hence, the findings may not be readily generalized to the broader patient population.
引用
收藏
页码:820 / 830
页数:11
相关论文
共 28 条
[1]   A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures [J].
Aldenkamp, AP ;
Baker, G ;
Mulder, OG ;
Chadwick, D ;
Cooper, P ;
Doelman, J ;
Duncan, R ;
Gassmann-Mayer, C ;
de Haan, GJ ;
Hughson, C ;
Hulsman, J ;
Overweg, J ;
Pledger, G ;
Rentmeester, TW ;
Riaz, H ;
Wroe, S .
EPILEPSIA, 2000, 41 (09) :1167-1178
[2]   Randomized dose-controlled study of topiramate as first-line therapy in epilepsy [J].
Arroyo, S ;
Dodson, WE ;
Privitera, MD ;
Glauser, TA ;
Naritoku, DK ;
Dlugos, DJ ;
Wang, S ;
Schwabe, SK ;
Twyman, RE .
ACTA NEUROLOGICA SCANDINAVICA, 2005, 112 (04) :214-222
[3]   Topiramate pharmacokinetics in children and adults with epilepsy - A case-matched comparison based on therapeutic drug monitoring data [J].
Battino, D ;
Croci, D ;
Rossini, A ;
Messina, S ;
Mamoli, D ;
Perucca, E .
CLINICAL PHARMACOKINETICS, 2005, 44 (04) :407-416
[4]   Topiramate pharmacokinetics in infants and young children: Contribution of population analysis [J].
Bouillon-Pichault, Marion ;
Nabbout, Rima ;
Chhun, Stephanie ;
Rey, Elisabeth ;
Chiron, Catherine ;
Dulac, Olivier ;
Pons, Gerard ;
Jullien, Vincent .
EPILEPSY RESEARCH, 2011, 93 (2-3) :208-211
[5]  
Bourgeois Blaise F. D., 2000, Journal of Child Neurology, V15, pS27
[6]   Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine [J].
Britzi, M ;
Perucca, E ;
Soback, S ;
Levy, RH ;
Fattore, C ;
Crema, F ;
Gatti, G ;
Doose, DR ;
Maryanoff, BE ;
Bialer, M .
EPILEPSIA, 2005, 46 (03) :378-384
[7]   Genetic and environmental correlates of topiramate-induced cognitive impairment [J].
Cirulli, Elizabeth T. ;
Urban, Thomas J. ;
Marino, Susan E. ;
Linney, Kristen N. ;
Birnbaum, Angela K. ;
Depondt, Chantal ;
Attix, Deborah K. ;
Radtke, Rodney A. ;
Goldstein, David B. .
EPILEPSIA, 2012, 53 (01) :e5-e8
[8]  
Clarks AM, 2011, DEV INTRAVENOUS TOPI
[9]  
Garnett WR, 2000, EPILEPSIA, V41, pS61
[10]   A dose-comparison trial of topiramate as monotherapy in recently diagnosed partial epilepsy [J].
Gilliam, FG ;
Veloso, F ;
Bomhof, MAM ;
Gazda, SK ;
Biton, V ;
Ter Bruggen, JP ;
Neto, W ;
Bailey, C ;
Pledger, G ;
Wu, SC .
NEUROLOGY, 2003, 60 (02) :196-202